Nutriventia launches new sustained release ashwagandha

22-Sep-2022

The new product, named Prolanza, has been unveiled alongside a new study illustrating its impressive duration of therapeutic effects

Nutriventia launches new sustained release ashwagandha

India-based Nutriventia, has announced the launch of sustained-release Prolanza ashwagandha (Withania somnifera), backed by a study showing its superior absorption to other products. 

In the new study, the pharmacokinetics, safety, and tolerability in equi-dose format compared 600mg of Prolanza  sustained release capsules containing 30mg of withanolides with 600mg of a well-known ashwagandha extract. 14 Participants were randomised to receive either the test or the reference product as a single dose of 2 capsules in sequence, administered under fasting conditions. Plasma concentrations of total withanolides, withanolide A and 12-deoxywithastramonolide were measured using validated liquid chromatography–mass spectroscopy/mass spectroscopy.

The research showed that Prolanza ashwagandha exhibited a higher relative absorption, better bioavailability, and longer elimination half-life than the control ingredient, indicating a sustained-release profile. Specifically, they asserted: “the relative bioavailability of the test formulation was 12, 44, and 11 times higher for total withanolides, withanolide A and 12-deoxywithastramonolide, respectively.”

The sustained-release profile of the test product, compared to the reference product, will provide more long-lasting therapeutic effects from a single daily dose. The pharmacokinetic study also reports for first time, the successful plasma estimation of withanolide A and 12-deoxywithastraamonolide, the major phytoactives of ashwagandha.

As ashwagandha is primarily consumed for its adaptogenic and stress response-reduction properties, the longer duration of Prolanza’s therapeutic effects will provide a stronger cumulative health value

“As ashwagandha is primarily consumed for its adaptogenic and stress response-reduction properties, the longer duration of Prolanza’s therapeutic effects will provide a stronger cumulative health value,” said Anand Godbole, Nutriventia vice president of marketing. 

“Consumers are looking for efficient products that will make their lives even a little easier. Prolanza™ provides that, plus convenience for our customers. Now with our clinical study showing adaptogenic support for a prolonged period, it makes Prolanza an ideal ingredient to help manage the grind of daily stress more efficiently.”

“Consumers will be able to enjoy a higher sense of well-being and good health sooner with Prolanza™ sustained-release ashwagandha.”

Prolanza, the new-age Ashwagandha root-only extract, provides all-day support for stress management. The innovative release pattern of Prolanza enables it to exert its clinical benefits for a prolonged duration with a single daily dose. Prolanza has a broad spectrum of 20 withanolides, including 10 USP withanolides. 

Nutriventia, Inventia Healthcare's health and wellness brand, is at the cusp of science and nature. The journey at Inventia began almost four decades ago, when two scientists with deep-rooted knowledge in medical sciences, ventured out to develop solutions that were an improvement on generic products becoming the pioneers of NDDS products in India. Today, Nutriventia is a preferred partner to multinational and Indian transnational companies for their global requirements. Nutriventia uses proprietary and patented processes to improve ingredients by addressing issues and concerns in manufacturing, formulation, clinical research.

Sign up for your free email newsletter


 

Companies